GlassScriptPhysician profile
Mohammad H Razavi
NPI 1639167661
$8,886.21
in general payments reported to CMS, 2019-2025
27 companies · $2,705 in 2025
The $2,705 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $105 · 2021: $568 · 2022: $1,576 · 2023: $1,061 · 2024: $1,864 · 2025: $2,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,630.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,134.56 | 2019-2025 | |
| Gilead Sciences, INC. | $950.83 | 2019-2025 | Livdelzi, Vemlidy |
| Phathom Pharmaceuticals, INC. | $894.07 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $686.08 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $678.03 | 2020-2025 | Tremfya, Stelara, Remicade |
| Braintree Laboratories, INC. | $547.00 | 2019-2025 | Sutab, Suflave |
| Ardelyx, INC. | $415.24 | 2024-2025 | Ibsrela |
| Pfizer INC. | $403.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $331.92 | 2019-2023 | Trulance |
| Madrigal Pharmaceuticals | $331.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $211.99 | 2019-2022 | |
| Qol Medical, LLC | $165.65 | 2022-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $142.37 | 2025 | Zenpep |
| W. L. Gore & Associates, INC. | $137.78 | 2023 | Gore Viabahn Endoprosthesis |
| Regeneron Healthcare Solutions, INC. | $133.54 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $127.01 | 2021-2025 | Entyvio |
| Amgen INC. | $125.00 | 2022 | |
| Terumo Medical Corporation | $115.36 | 2019 | |
| Celgene Corporation | $108.44 | 2021-2024 | Zeposia |
| Genzyme Corporation | $74.72 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $42.36 | 2021-2022 | |
| Redhill Biopharma INC. | $35.37 | 2021-2022 | |
| Ethicon US, LLC | $23.26 | 2022 | |
| Celltrion USA INC. | $20.96 | 2025 | Vegzelma |
| Boston Scientific Corporation | $19.94 | 2024 | Watchman Access System |
| Allergan, INC. | $17.23 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Razavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.